| Business Summary | | Organogenesis,
Inc.
is
a
tissue
engineering
company
that
designs,
develops
and
manufactures
medical
products
containing
living
cells
and/or
natural
connective
tissue.
The
Company
is
the
developer
and
manufacturer
of
the
only
mass-produced
product
containing
living
human
cells
to
gain
Food
and
Drug
Administration
(FDA)
marketing
approval.
The
Company's
lead
product,
Apligraf,
a
cellular,
bi-layered
skin
substitute,
is
FDA
approved
for
the
treatment
of
venous
leg
ulcers
and
diabetic
foot
ulcers;
Novartis
Pharma
AG
has
global
Apligraf
marketing
rights.
Organogenesis
is
leveraging
its
FortaFlex
bioengineered
collagen
matrix
technology
into
a
family
of
products,
and
has
recently
achieved
marketing
clearance
for
its
FortaPerm
surgical
sling
and
PuraPly
wound
dressing.
The
Organogenesis
research
pipeline
includes
the
Vitrix
living
dermal
replacement,
a
coronary
vascular
graft
and
a
liver
assist
device. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Organogenesis,
Inc.
designs,
develops
and
manufactures
medical
therapeutics
containing
living
cells
and/or
natural
connective
tissue.
For
the
six
months
ended
6/30/01,
total
revenues
fell
38%
to
$4.6
million.
Net
loss
before
accounting
change
increased
84%
to
$15.1
million.
Revenues
reflect
the
absence
of
a
$5
million
milestone
payment
from
Novartis
related
to
diabetic
foot
ulcers.
Loss
also
reflects
$1.2
million
in
severance
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Albert Erani, 60 Chairman | -- | -- | Michael Sabolinski, M.D., 45 Pres,
CEO, Director | $283K | $105K | John Arcari, 55 CFO,
VP of Fin. and Admin., Sec., Treasurer | 119K | -- | Nancy Parenteau, Ph.D., 47 Sr.
VP of R&D and CSO | 273K | -- | Paul DiCicco, 49 VP-Operations | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|